Daniel Char Net Worth

Daniel Char biography

Daniel S. Char J.D. serves as General Counsel, Secretary of the Company. Mr. Char was the Associate General Counsel - Commercial of Smith & Nephew, a medical technology and biopharmaceutical company, from November 2009 to March 2018. From March 2008 to March 2009, Mr. Char was the General Counsel and Secretary of Targanta Therapeutics, a biopharmaceutical company developing novel antibiotics. Mr. Char received his J.D. from Harvard Law School.

How old is Daniel Char?

Daniel Char is 59, he's been the General Counsel and Secretary of Evelo Biosciences Inc since 2018. There are 4 older and 9 younger executives at Evelo Biosciences Inc. The oldest executive at Evelo Biosciences Inc is Stephen J. Carriere, 66, who is the VP & Chief Accounting Officer.

What's Daniel Char's mailing address?

Daniel's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.

Insiders trading at Evelo Biosciences Inc

Over the last 6 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan, and Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.

What does Evelo Biosciences Inc do?

evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag

Evelo Biosciences Inc executives and stock owners

Evelo Biosciences Inc executives and other stock owners filed with the SEC include:

• Balkrishan Gill,
  President, Chief Executive Officer, Principal Financial Officer, Treasurer, Director
• Mark Bodmer,
  Chief Scientific Officer, President of Research and Development
• David Epstein,
  Chairman of the Board
• Theodose Melas-Kyriazi,
  Independent Director
• Nancy Simonian,
  Independent Director
• Lord Ara Darzi,
  Independent Director
• David Perry,
  Independent Director
• Juan Andres,
  Independent Director
• Duncan McHale,
  Chief Medical Officer
• Daniel Char,
  General Counsel, Secretary
• Xiaoli Liu,
  Principal Accounting Officer, Controller
• Leslie Wardwell-Scott Ph.D.,
  Head of Corp. Devel. & Strategic Integration
• Jessica Cotrone,
  VP & Head of Communications
• Daniel S. Char,
  Gen. Counsel & Sec.
• Kendra Sweeney,
  Head of Investor Relations & Capital Markets
• Dr. Chun Zhang,
  Head of Technical Operations
• Stephen J. Carriere,
  VP & Chief Accounting Officer
• Luca Scavo,
  CFO, Sr. VP & Treasurer
• Dr. Duncan McHale M.D., Ph.D.,
  Chief Medical Officer
• Dr. Balkrishan Gill Ph.D.,
  Pres, CEO & Director
• Julie Mc Hugh,
  Director
• Alexander C Reynolds,
  Director
• Jeffrey R. Moore,
  Director
• Kyriazi Theo Melas,
  Director
• Noubar Afeyan,
  Director
• Ventures Fund Iv General Pa...,
  
• Jose Carlos Gutierrez Ramos,
  Director
• Simba Gill,
  President & CEO
• Jonathan Poole,
  CFO
• Ventures Fund Iv General Pa...,
  
• Ventures Fund V General Par...,
  
• Robert L. Rosiello,
  Director
• Tonya Williams,
  Director
• Iain B. Mc Innes,
  Director
• Neil Graham,
  Chief Development Officer
• Ventures Fund Iv General Pa...,
  
• Ventures Fund Iv General Pa...,
  
• Jonathan B. Zung,
  Chief Development Officer
• John Hohneker,
  Director
• Stephen J Carriere,
  Principal Accounting Officer
• Mark D. Plinio,
  Chief Commercial Officer
• Luca Scavo,
  CFO
• Ventures Fund Iv General Pa...,
  
• Marella Thorell,
  Chief Financial Officer